PR92296

SHANGHAI, Oct. 13, 2021 /PRNewswire=KYODO JBN/ --

-Head of the Chinese oncology genomic testing company shared their recent

findings on early screening for multiple high-risk cancers

Berry Oncology, a Chinese oncology genomic testing company, was invited to the

inaugural International Biopharma Industry Week in Shanghai (IBIWS) running

from October 11-14, where CEO Jun Zhou delivered a much-anticipated keynote

speech at the "2021 Future Healthcare Industry Summit" subforum, unveiling the

company's latest research results on early screening for multiple cancers.

The advanced results of the study cover a higher proportion of early-stage

patients: 73% of stage I and II samples overall, and 69.6% and 92.9%

sensitivity in stage I and II samples respectively, which significantly

outperforms data models of other top-tier international companies of its kind.

With the HIFI method, a liquid biopsy, platform-based technology developed by

Berry Oncology, a single test can early screen for six major high-risk cancers

in China, including liver, lung, gastric, colorectal, esophageal and pancreatic

cancers, with an overall sensitivity of 87.6%, specificity of 99.1% and overall

TOO (Tissue of Origin) precision in 82% of positive cancers, elevating test

performance to an advanced international level.  

Jun Zhou said, "In this multi-cancer early screening study, Berry Oncology

specifically chose lung and gastrointestinal cancers as the breakthrough point

as they pose the highest threat in terms of morbidity and mortality in China.

From the outset of our product design, we specifically took into account the

tumorigenic characteristics of the Chinese population and which cancer most

urgently needs early screening solutions."

Notably, the detection of pancreatic cancer, one of the most challenging and

malignant of cancers, has once again demonstrated the extraordinary performance

of Berry Oncology's early screening technology, with a sensitivity and

specificity of over 90% and an area under the curve (AUC) of 0.975.

As one of the earliest Chinese companies engaged in the early screening of

cancers, Berry Oncology is the first to apply its self-developed HIFI method to

the early screening of liver and lung cancers. At CSCO 2021, Berry Oncology

announced the results of a pilot study on early screening of lung cancer, in

which HIFI technology was validated with an AUC of 0.912 in a sample cohort

that better matches the characteristics of Chinese patients, with 80.9% of

stage I lung cancers and 89.2% of lung adenocarcinomas.

Visit Berry Oncology.

SOURCE:Berry Oncology

Image Attachments Links:

   Link: http://asianetnews.net/view-attachment?attach-id=403797

   Caption: Berry Oncology